TNC and adenocarcinoma: Among the other regulators from cluster #7 found as frequently changed according to cBioPortal, there is, for example, frequently mutated or upregulated TNC (changed in 12.8% of adenocarcinoma cases), tenascin C, that promotes the expression of matrix metallopeptidases and was proposed as prognostic biomarker of CRC in many studies [49], [50].